National Institute on Aging; Notice of Closed Meeting, 1580-1581 [2024-00283]
Download as PDF
lotter on DSK11XQN23PROD with NOTICES1
1580
Federal Register / Vol. 89, No. 7 / Wednesday, January 10, 2024 / Notices
on Neurocognitive Development and
Addiction Risk (TranSINDA).
Date: February 9, 2024.
Time: 1:00 p.m. to 4:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
National Institute on Drug Abuse, 301 North
Stonestreet Avenue, Bethesda, MD 20892
(Virtual Meeting).
Contact Person: Caitlin Elizabeth Angela
Moyer, Ph.D., Scientific Review Officer,
Scientific Review Branch, National Institute
on Drug Abuse, NIH, 301 North Stonestreet
Avenue, MSC 6021, Bethesda, MD 20892,
(301) 443–4577, caitlin.moyer@nih.gov.
Name of Committee: National Institute on
Drug Abuse Special Emphasis Panel;
Chemical Countermeasures Research
Program Initiative: Research on
Counteracting the Deleterious Effects of
Acute Opioid Exposure.
Date: February 15, 2024.
Time: 12:30 p.m. to 4:30 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
National Institute on Drug Abuse, 301 North
Stonestreet Avenue, Bethesda, MD 20892
(Virtual Meeting).
Contact Person: Li Rebekah Feng, Ph.D.,
Scientific Review Officer, Scientific Review
Branch, National Institute on Drug Abuse,
NIH, 301 North Stonestreet Avenue, MSC
6021, Bethesda, MD 20892, (301) 827–7245,
rebekah.feng@nih.gov.
Name of Committee: National Institute on
Drug Abuse Special Emphasis Panel;
Advancing Psychedelics Research for
Treating Addiction.
Date: February 21, 2024.
Time: 11:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
National Institute on Drug Abuse, 301 North
Stonestreet Avenue, Bethesda, MD 20892
(Virtual Meeting).
Contact Person: Brian Stefan Wolff, Ph.D.,
Scientific Review Officer, Scientific Review
Branch, Division of Extramural Research,
National Institute on Drug Abuse, NIH, 301
North Stonestreet Avenue, MSC 6021,
Bethesda, MD 20852, (301) 480–1448,
brian.wolff@nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.277, Drug Abuse Scientist
Development Award for Clinicians, Scientist
Development Awards, and Research Scientist
Awards; 93.278, Drug Abuse National
Research Service Awards for Research
Training; 93.279, Drug Abuse and Addiction
Research Programs, National Institutes of
Health, HHS)
Dated: January 5, 2024.
Lauren A. Fleck,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2024–00361 Filed 1–9–24; 8:45 am]
BILLING CODE 4140–01–P
VerDate Sep<11>2014
16:40 Jan 09, 2024
Jkt 262001
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Center for Scientific Review; Notice of
Closed Meetings
Pursuant to section 1009 of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: Center for Scientific
Review Special Emphasis Panel; PAR–22–
233: Time-Sensitive Opportunities for Health
Research.
Date: January 29, 2024.
Time: 9:00 a.m. to 7:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Rockledge II, 6701 Rockledge Drive,
Bethesda, MD 20892 (Virtual Meeting).
Contact Person: Hoa Thi Vo, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 1002B2,
Bethesda, MD 20892, (301) 594–0776, voht@
csr.nih.gov.
Name of Committee: Integrative,
Functional and Cognitive Neuroscience
Integrated Review Group, Behavioral
Neuroendocrinology, Neuroimmunology,
Rhythms, and Sleep Study Section.
Date: February 1–2, 2024.
Time: 9:00 a.m. to 8:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Rockledge II, 6701 Rockledge Drive,
Bethesda, MD 20892 (Virtual Meeting).
Contact Person: Michael Selmanoff, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 5164,
MSC 7844 Bethesda, MD 20892, 301–435–
1119, selmanom@csr.nih.gov.
Name of Committee: Risk, Prevention and
Health Behavior Integrated Review Group,
Psychosocial Development, Risk and
Prevention Study Section.
Date: February 1–2, 2024.
Time: 9:00 a.m. to 8:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Rockledge II, 6701 Rockledge Drive,
Bethesda, MD 20892 (Virtual Meeting).
Contact Person: Anna L Riley, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
PO 00000
Frm 00072
Fmt 4703
Sfmt 4703
Health, 6701 Rockledge Drive, Room 3114,
MSC 7759 Bethesda, MD 20892, 301- 435–
2889, rileyann@csr.nih.gov.
Name of Committee: Bioengineering
Sciences & Technologies Integrated Review
Group; Drug and Biologic Therapeutic
Delivery Study Section.
Date: February 1–2, 2024.
Time: 9:00 a.m. to 6:00 p.m.
Agenda: To review and evaluate grant
applications
Place: National Institutes of Health
Rockledge II 6701 Rockledge Drive, Bethesda,
MD 20892 (Virtual Meeting).
Contact Person: Janice Duy, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, 6701 Rockledge Drive,
Bethesda, MD 20892, 301–594–3139,
janice.duy@nih.gov.
Name of Committee: Population Sciences
and Epidemiology Integrated Review Group;
Social Sciences and Population Studies A
Study Section.
Date: February 1–2, 2024.
Time: 10:00 a.m. to 8:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Rockledge II, 6701 Rockledge Drive,
Bethesda, MD 20892 (Virtual Meeting).
Contact Person: Suzanne Ryan, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 3139,
MSC 7770 Bethesda, MD 20892, (301) 435–
1712, ryansj@csr.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.306, Comparative Medicine;
93.333, Clinical Research, 93.306, 93.333,
93.337, 93.393–93.396, 93.837–93.844,
93.846–93.878, 93.892, 93.893, National
Institutes of Health, HHS)
Dated: January 4, 2024.
Miguelina Perez,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2024–00290 Filed 1–9–24; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute on Aging; Notice of
Closed Meeting
Pursuant to section 1009 of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
E:\FR\FM\10JAN1.SGM
10JAN1
Federal Register / Vol. 89, No. 7 / Wednesday, January 10, 2024 / Notices
would constitute a clearly unwarranted
invasion of personal privacy.
of automated collection techniques or
other forms of information technology.
Name of Committee: National Institute on
Aging Special Emphasis Panel; Alpha Herpes
Viruses and Alzheimer’s Disease Progression.
Date: January 26, 2024.
Time: 12:00 p.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institute on Aging,
Gateway Building, 7201 Wisconsin Avenue,
Bethesda, MD 20892 (Virtual Meeting).
Contact Person: Ivan Tadeu Rebustini,
Ph.D., Scientific Review Branch, NIA, 7201
Wisconsin Ave., Rm 100, Bethesda, MD
20814, (301) 555–1212, ivan.rebustini@
nih.gov.
This notice is being published less than 15
days prior to the meeting due to the timing
limitations imposed by the review and
funding cycle.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.866, Aging Research,
National Institutes of Health, HHS)
Project: 2023–2026 Advancing Wellness
and Resilience in Education and
Trauma Informed Services in Schools
Cross-Site Evaluation—New Collection
The Substance Abuse and Mental
Health Services Administration
(SAMHSA) Center for Mental Health
Services (CMHS) is requesting clearance
for data collection associated with a
national cross-site evaluation of process,
outcomes, and impact for the Advancing
Wellness and Resilience in Education
(hereinafter referred to as Project
AWARE) and Trauma-Informed Services
in Schools (TISS) programs.
The purpose of the Project AWARE–
TISS Cross-Site Evaluation is to better
understand how each program is
implemented, the extent to which they
facilitate collaboration between
education agencies and mental health
systems, and how each program
contributes to access and referral to
mental health services and improved
outcomes for youth.
The AWARE–TISS Cross-Site
Evaluation incorporates four evaluation
components to provide a robust
understanding of the implementation
(process), outcomes, and associated
impacts of the AWARE and TISS
Programs and includes program-specific
components to ensure programmatic
differences and commonalities are
understood. With this integrated
evaluation design, SAMHSA maintains
the ability to evaluate and report on
each program separately, while
additionally benefiting from the ability
to understand the overarching impact of
both programs collectively.
Approval is being requested for data
collection associated with a Process
Evaluation and an Outcome Evaluation.
Several program specific sub-studies
and cross-program impact analyses will
also be conducted to assess
implementation and outcomes overall as
well as those outcomes specific to highneed subpopulations and underresourced communities. A behavioral
health equity and cultural equity lens
will be applied to each area of
evaluation to ensure a culturally
specific understanding of intervention
implementation, outcomes, and
impacts.
The Process Evaluation will contain
two studies (Implementation and
Sustainability Study and Systems
Change Study) that examine strategies
common to both programs related to
program implementation facilitators and
barriers, workforce development, and
grantees’ plans to sustain critical
program components beyond their grant
Dated: January 4, 2024.
Miguelina Perez,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2024–00283 Filed 1–9–24; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Substance Abuse and Mental Health
Services Administration
lotter on DSK11XQN23PROD with NOTICES1
Agency Information Collection
Activities: Proposed Collection;
Comment Request
In compliance with section
3506(c)(2)(A) of the Paperwork
Reduction Act of 1995 concerning
opportunity for public comment on
proposed collections of information, the
Substance Abuse and Mental Health
Services Administration (SAMHSA)
will publish periodic summaries of
proposed projects. To request more
information on the proposed projects or
to obtain a copy of the information
collection plans, contact the SAMHSA
Reports Clearance Officer at
samhsapra@samhsa.hhs.gov.
Comments are invited on: (a) whether
the proposed collections of information
are necessary for the proper
performance of the functions of the
agency, including whether the
information shall have practical utility;
(b) the accuracy of the agency’s estimate
of the burden of the proposed collection
of information; (c) ways to enhance the
quality, utility, and clarity of the
information to be collected; and (d)
ways to minimize the burden of the
collection of information on
respondents, including through the use
VerDate Sep<11>2014
16:40 Jan 09, 2024
Jkt 262001
PO 00000
Frm 00073
Fmt 4703
Sfmt 4703
1581
period. This assessment of common
elements will provide a means to
compare the implementation strategies
that are successful across both AWARE
and TISS grantees and identify
successes and challenges in changing
systems, policies, service provision, and
school climate; increasing behavioral
health equity in access and service
delivery; and increasing social and
emotional development and well-being
in school-aged children and youth. The
Process Evaluation will also address
implementation of program-specific
components.
For AWARE, the evaluation will
document how the grantees implement
the three-tiered public health model in
schools and the referral pathways to
increase access to mental health
promotion, prevention, and
intervention. The evaluation will assess
the grantee collaborative efforts and
grantee activities intended to increase
workforce capacity to identify the signs
and symptoms of mental illness and
ability to refer to appropriate services
promptly.
For TISS, the Process Evaluation will
focus on examining what innovative
strategies the grantees use to increase
access to trauma informed services for
school-aged youth and how the
collaborative efforts of grantees and
their partners develop/improve a
school-based system for identification,
referral, early intervention, treatment,
and supportive services. Additionally,
the Process Evaluation will assess the
implementation of training to improve
school capacity to address trauma
support needs and engagement of
families and communities to increase
awareness of the effects of trauma on
children and youth.
The Outcome Evaluation will include
two studies that examine important
facets of the AWARE and TISS
programs: (1) identification and referral
infrastructure (Identification and
Referral Study); and (2) youth resiliency
and outcomes (Youth Resiliency and
Outcomes Study). Both studies will
provide critical information about the
effectiveness of the AWARE and TISS
programs in establishing and enhancing
school-based mental health supports for
students.
Program specific sub-studies,
inclusive of two TISS case studies and
an AWARE Suicide Awareness and
Prevention Sub-Study, will be
conducted to provide more extensive
contextual and implementation
information related to the AWARE and
TISS programs.
Finally, in addition to assessing the
process and outcomes of each of the
AWARE and TISS programs, we will
E:\FR\FM\10JAN1.SGM
10JAN1
Agencies
[Federal Register Volume 89, Number 7 (Wednesday, January 10, 2024)]
[Notices]
[Pages 1580-1581]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2024-00283]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
National Institute on Aging; Notice of Closed Meeting
Pursuant to section 1009 of the Federal Advisory Committee Act, as
amended, notice is hereby given of the following meeting.
The meeting will be closed to the public in accordance with the
provisions set forth in sections 552b(c)(4) and 552b(c)(6), title 5
U.S.C., as amended. The grant applications and the discussions could
disclose confidential trade secrets or commercial property such as
patentable material, and personal information concerning individuals
associated with the grant applications, the disclosure of which
[[Page 1581]]
would constitute a clearly unwarranted invasion of personal privacy.
Name of Committee: National Institute on Aging Special Emphasis
Panel; Alpha Herpes Viruses and Alzheimer's Disease Progression.
Date: January 26, 2024.
Time: 12:00 p.m. to 5:00 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institute on Aging, Gateway Building, 7201
Wisconsin Avenue, Bethesda, MD 20892 (Virtual Meeting).
Contact Person: Ivan Tadeu Rebustini, Ph.D., Scientific Review
Branch, NIA, 7201 Wisconsin Ave., Rm 100, Bethesda, MD 20814, (301)
555-1212, [email protected].
This notice is being published less than 15 days prior to the
meeting due to the timing limitations imposed by the review and
funding cycle.
(Catalogue of Federal Domestic Assistance Program Nos. 93.866, Aging
Research, National Institutes of Health, HHS)
Dated: January 4, 2024.
Miguelina Perez,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2024-00283 Filed 1-9-24; 8:45 am]
BILLING CODE 4140-01-P